623持股的美国生命治疗公司将公开募股8600万美元，真消息，有传送门

在别的吧里看到这碗已经失传很久的冷饭，Google查了一下，应该是真的，几年前的冷饭会不会又拿出来炒呢？

给个传送门。
http://www.fiercebiotech.com/story/vital-therapies-plots-86m-ipo-biotech-market-boils/2013-10-11
正文：
Vital Therapies plots $86M IPO as biotech market boils

Read more: Vital Therapies plots $86M IPO as biotech market boils - FierceBiotech http://www.fiercebiotech.com/story/vital-therapies-plots-86m-ipo-biotech-market-boils/2013-10-11#ixzz2jDQiyQFI
Subscribe at FierceBiotech
San Diego‘s Vital Therapies has filed for an $86.3 million IPO, eyeing a piece of the burgeoning market for biotechs on Wall Street as it advances a novel treatment for liver failure.

Planning to trade on the Nasdaq under "VTL," the company will use its IPO proceeds to bankroll three Phase III studies of Elad, a biologic cellular therapy system for crumbling livers. Elad works by running patients‘ blood through a bedside unit that uses human liver-derived cancer cells to filter toxins out of the plasma, which is then pumped back into the patient, restoring liver function.

Vital Therapies expects to have pivotal data of Elad‘s effects on alcohol-induced liver decompensation ready to go by 2015, with Phase III trials on acute alcoholic hepatitis and fulminant hepatic failure wrapping up in 2016 and 2017. The company is also in the midst of preclinical work to see whether Elad can be of use in liver transplants and liver cancer resections.

Read more: Vital Therapies plots $86M IPO as biotech market boils - FierceBiotech http://www.fiercebiotech.com/story/vital-therapies-plots-86m-ipo-biotech-market-boils/2013-10-11#ixzz2jDQf7Z00
Subscribe at FierceBiotech